Skip to main content
Erschienen in: Familial Cancer 4/2007

01.12.2007

A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families

verfasst von: Patricia N. Tonin, Christine M. Maugard, Chantal Perret, Anne-Marie Mes-Masson, Diane M. Provencher

Erschienen in: Familial Cancer | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Pathogenic mutations in BRCA1 and BRCA2 have been reported in about 55–59% of breast and ovarian cancer (HBOC) families of French Canadian descent, where about 70% of families with more than two cases of ovarian cancer were mutation-positive. Given that specific subtypes of ovarian cancer are associated with mutation-positive families, we reviewed the features of 54 HBOC families of French Canadian descent that had histopathologically confirmed cases of invasive ovarian cancer where the BRCA1 and BRCA2 mutation status is known, and 27 families harbored germline mutations. The number of cases and ages of diagnosis of either breast cancers or ovarian cancers did not differ significantly in comparisons of mutation-positive and mutation-negative groups. However, the distribution of histopathological subtypes for the 79 cases of invasive epithelial cancer from the 54 HBOC families differed when grouped according to familial mutation status. The mutation-negative group had significantly more cases of the mucinous subtype of ovarian cancer when compared with the BRCA1 (P = 0.005) and BRCA2 (P = 0.017) mutation-positive groups. The presence of a mucinous subtype ovarian cancer in multiple young age of onset breast and/or ovarian mutation-negative HBOC cancer families warrants further investigation, as these families appear to exhibit features most consistent with BRCA1 and BRCA2 carrier status.
Literatur
1.
Zurück zum Zitat Tonin PN et al (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63(5):1341–1351PubMedCrossRef Tonin PN et al (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63(5):1341–1351PubMedCrossRef
2.
Zurück zum Zitat Oros KK et al (2004) Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 112(3):411–419PubMedCrossRef Oros KK et al (2004) Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 112(3):411–419PubMedCrossRef
3.
Zurück zum Zitat Oros KK et al (2006) Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet 70(4):320–329PubMedCrossRef Oros KK et al (2006) Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet 70(4):320–329PubMedCrossRef
4.
Zurück zum Zitat Simard J et al (1994) Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8(4):392–398PubMedCrossRef Simard J et al (1994) Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8(4):392–398PubMedCrossRef
5.
Zurück zum Zitat Manning AP et al (2001) Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered 52(2):116–120PubMedCrossRef Manning AP et al (2001) Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered 52(2):116–120PubMedCrossRef
6.
Zurück zum Zitat Vezina H et al (2005) Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French–Canadian breast/ovarian cancer families. Hum Genet 117(2–3):119–132PubMedCrossRef Vezina H et al (2005) Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French–Canadian breast/ovarian cancer families. Hum Genet 117(2–3):119–132PubMedCrossRef
7.
Zurück zum Zitat Oros KK et al (2006) Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet 7(1):23PubMedCrossRef Oros KK et al (2006) Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Med Genet 7(1):23PubMedCrossRef
8.
Zurück zum Zitat Scriver CR (2001) Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2:69–101PubMedCrossRef Scriver CR (2001) Human genetics: lessons from Quebec populations. Annu Rev Genomics Hum Genet 2:69–101PubMedCrossRef
9.
Zurück zum Zitat Laberge AM et al (2005) Population history and its impact on medical genetics in Quebec. Clin Genet 68(4):287–301PubMedCrossRef Laberge AM et al (2005) Population history and its impact on medical genetics in Quebec. Clin Genet 68(4):287–301PubMedCrossRef
10.
Zurück zum Zitat Miki Y et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef Miki Y et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef
11.
Zurück zum Zitat Wooster R et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792PubMedCrossRef Wooster R et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792PubMedCrossRef
12.
Zurück zum Zitat Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRef Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRef
13.
Zurück zum Zitat Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689PubMedCrossRef Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689PubMedCrossRef
14.
Zurück zum Zitat Liede A et al (1998) Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet 75(1):55–58PubMedCrossRef Liede A et al (1998) Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet 75(1):55–58PubMedCrossRef
15.
Zurück zum Zitat Walsh T et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama 295(12):1379–1388PubMedCrossRef Walsh T et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama 295(12):1379–1388PubMedCrossRef
16.
Zurück zum Zitat Smith P et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655PubMedCrossRef Smith P et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655PubMedCrossRef
17.
Zurück zum Zitat Antoniou AC et al (2006) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French–Canadian families. Breast Cancer Res 8(1):R3PubMedCrossRef Antoniou AC et al (2006) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French–Canadian families. Breast Cancer Res 8(1):R3PubMedCrossRef
18.
Zurück zum Zitat Simard J et al (2006) Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multi-step testing approach in French-Canadian high-risk breast and ovarian cancer families. J Med Genet 44(2):107–121 Simard J et al (2006) Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multi-step testing approach in French-Canadian high-risk breast and ovarian cancer families. J Med Genet 44(2):107–121
19.
Zurück zum Zitat Moisan AM et al (2006) No evidence of BRCA1/2 genomic rearrangements in high-risk French–Canadian breast/ovarian cancer families. Genet Test 10(2):104–115PubMedCrossRef Moisan AM et al (2006) No evidence of BRCA1/2 genomic rearrangements in high-risk French–Canadian breast/ovarian cancer families. Genet Test 10(2):104–115PubMedCrossRef
20.
Zurück zum Zitat Lee JS et al (2006) Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 15(2):359–363PubMedCrossRef Lee JS et al (2006) Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev 15(2):359–363PubMedCrossRef
21.
22.
Zurück zum Zitat Canada C.C.S.N.C.I.o (2006) Canadian cancer statistic 2006. Toronto, Canada Canada C.C.S.N.C.I.o (2006) Canadian cancer statistic 2006. Toronto, Canada
24.
Zurück zum Zitat Godard B et al (1998) Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 179(2):403–410PubMedCrossRef Godard B et al (1998) Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 179(2):403–410PubMedCrossRef
25.
Zurück zum Zitat Tonin PM et al (1999) Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 55(5):318–324PubMedCrossRef Tonin PM et al (1999) Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 55(5):318–324PubMedCrossRef
Metadaten
Titel
A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families
verfasst von
Patricia N. Tonin
Christine M. Maugard
Chantal Perret
Anne-Marie Mes-Masson
Diane M. Provencher
Publikationsdatum
01.12.2007
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2007
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9152-x

Weitere Artikel der Ausgabe 4/2007

Familial Cancer 4/2007 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.